arrow
K

Katerina Politi

yaleResearch Fellow
H指数:54
被引数:2.0万

个人简介

Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus's lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as a Professor in the Department of Pathology and Yale Cancer Center.

教育背景

  • 2003.12

    Columbia University PhD Genetics and Development

工作经历

  • 2008.12

    Memorial Sloan-Kettering Cancer Center

    Research Fellow

  • 2010.12

    Memorial Sloan-Kettering Cancer Center

    Senior Research Scientist

  • 2003.12

    Columbia University

    Postdoctoral Research Scientist

荣誉奖项

暂无内容

Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification

表观遗传启动促进酪氨酸激酶抑制剂耐药性和癌基因扩增

2025-10-230
OAAI
The Polycomb Protein EED Constrains the SCLC Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation

多梳蛋白EED限制小细胞肺癌神经内分泌表型并驱动肺癌组织学转化

2025-08-290
PRE
Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC

2025年肺癌基础与转化研究进展——聚焦NSCLC的概述与展望

2025-06-030
PRE
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer

缺氧与肺癌对免疫检查点抑制剂的获得性耐药有关

2024-11-251
PRE
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)
2024-08-200
OA
Oncogenic context shapes the fitness landscape of tumor suppression
2023-10-125
OAAI
Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment

用于免疫肿瘤学的自体人源化PDX建模概括了人类肿瘤微环境的特征

2023-07-247
OAAI
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2023-06-1312
OA
Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment
2023-04-040
PRE